Discovery of novel 2,6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors

Article abstract of DOI:10.1016/j.ejmech.2013.01.056

2,6-Disubstituted pyridazinone 4 was identified by HTS as a novel acetylcholinesterase (AChE) inhibitor. Under SAR development, compound 17e stood out as displaying high AChE inhibitory activity and AChE/butyrylcholinesterase (BuChE) selectivity in vitro. Docking studies revealed that 17e might interact with the catalytic active site (CAS) and the peripheral anionic site (PAS) simultaneously. Based on this novel binding information, 6-ortho-tolylamino and N-ethyl-N-isopropylacetamide substituted piperidine were disclosed as new PAS and CAS binders.

Full text of DOI:10.1016/j.ejmech.2013.01.056

European Journal of Medicinal Chemistry 63 (2013) 95e103
Contents lists available at SciVerse ScienceDirect
European Journal of Medicinal Chemistry
journal homepage: http://www.elsevier.com/locate/ejmech
Original article
Discovery of novel 2,6-disubstituted pyridazinone derivatives
as acetylcholinesterase inhibitors
,
,
,
a,
*
Weiqiang Xing a 1, Yan Fu b 1, Zhangxing Shi a, Dong Lu a, Haiyan Zhang b , Youhong Hu
*
a State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road,
Shanghai 201203, China
b State Key Laboratory of Drug Research, Department of Neuropharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road,
Shanghai 201203, China
a r t i c l e i n f o
a b s t r a c t
Article history:
2,6-Disubstituted pyridazinone 4 was identified by HTS as a novel acetylcholinesterase (AChE) inhibitor.
Under SAR development, compound 17e stood out as displaying high AChE inhibitory activity and AChE/
butyrylcholinesterase (BuChE) selectivity in vitro. Docking studies revealed that 17e might interact with
the catalytic active site (CAS) and the peripheral anionic site (PAS) simultaneously. Based on this novel
binding information, 6-ortho-tolylamino and N-ethyl-N-isopropylacetamide substituted piperidine were
disclosed as new PAS and CAS binders.
Received 3 November 2012
Received in revised form
24 January 2013
Accepted 27 January 2013
Available online 8 February 2013
Ó 2013 Elsevier Masson SAS. All rights reserved.
Keywords:
Pyridazinone
Acetylcholinesterase
Alzheimer’s disease
Docking study
1. Introduction
quinoline [11e13], benzophenone [14,15], triazin [16], ferulic acid
[17] and naphthyridine [18] frameworks as the primary pharma-
Alzheimer’s disease (AD) is a complex neurodegenerative dis-
order of the central nervous system. It is estimated that nearly 36
million people worldwide are now suffering from AD, and the
figure would be increased to about 66 million by 2030 if no
breakthroughs were made. Acetylcholinesterase (AChE), a serine
protease, is responsible for acetylcholine hydrolysis and plays
a fundamental role in impulse transmission by terminating the
action of the neurotransmitter acetylcholine at the cholinergic
synapses and neuromuscular junction [1]. Among the various ap-
proaches for treating AD, inhibition of AChE is still prevailing in
treating or alleviating the symptoms of AD. Tacrine (1, Fig. 1),
a nonselective AChE/butyrylcholinesterase (BuChE) inhibitor, was
the first drug approved by FDA in 1993. Other selective inhibitors,
such as donepezil (2, Fig.1), also reached the market sequentially. In
recent years, novel AChE inhibitors are continuingly discovered
from natural resources or by synthetic approaches, bearing such as
cophoric scaffolds.
The most interesting structural character of AChE protein is the
presence of a deep narrow gorge, at the bottom of which a triad lies
in the catalytic anionic site (CAS). Besides, the peripheral anionic
site (PAS) lies at the entrance of the gorge as a regulatory site. Based
on these findings, Pang et al. first reported a tacrine dimer 3 (Fig. 1)
as a bivalent AChE inhibitor which interacts with CAS and PAS
simultaneously [19]. This compound displayed much higher AChE
inhibitory activity and specificity over BuChE than the parent
compound 1. Through this strategy, the second generation AChE
inhibitors are developed by utilizing one or two known scaffolds of
AChE inhibitor and most of them possess elevated potency and
improved AChE/BuChE selectivity profile [20e28].
Through an in vitro HTS campaign with diverse compounds li-
braries inhouse, pyridazinone derivative 4 (Fig. 1) stood out as
a potential AChE inhibitor with an IC50 of 1.66
mM. To our best
berberine [2e6], coumarin [7,8], benzofuran [9],
b
-carboline [10],
knowledge, only a few compounds bearing this scaffold were
reported with a liner pyridazine-donepezil hybrid 5 (Fig. 1) in the
literature [29e31], which behaved as a dual site binding inhibitor.
By optimizing the 3,6-substitutions on the pyridazine ring, high
AChE affinity of the compound was achieved. However, this type of
molecules displayed low AChE/BuChE selectivity, which might lead
* Corresponding authors.
E-mail addresses: hzhang@mail.shcnc.ac.cn (H. Zhang), yhhu@mail.shcnc.ac.cn
(Y. Hu).
1
Authors equally contributed to this work.
0223-5234/$ e see front matter Ó 2013 Elsevier Masson SAS. All rights reserved.
http://dx.doi.org/10.1016/j.ejmech.2013.01.056

96
W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
Table 1
AChE inhibitory activity of 6-aryl substituted pyridazinones.
No.
R
IC50
(
mM)
No.
R
IC50 (mM)
4
1.66
11d
0.623
0.648
0.462
10
H
4.90
2.61
11e
12a
11a
Fig. 1. Representative AChE inhibitors.
11b
11c
2.01
12b
12c
0.188
0.220
to undesirable peripheral side effects. As the compound 4 bears
different substituents on pyridazinone ring from 5a/5b and does
not share any structural similarity with donepezil, we realized that
the SAR of 4 might not parallel with that of 5a/5b or donepezil, thus
leading this de novo pyridazinone molecule to be worth of opti-
mization for finding diverse AChE inhibitors with high potency and
AChE/BuChE selectivity.
0.746
affinity. Compound 11c, a meta-methyl substituted pattern, dis-
played a slight enhancement in activity with an IC50 of 0.746 M.
m
Besides, other meta-halo substituted analogs (11dee) remained
biological activity at enzymatic level. When the conjugated system
in 4 was extended by replacing the phenyl with naphthyl (12aeb),
or by adding a cyano group on meta position (12c), the potency of
compounds was evidently enhanced. The most promising com-
2. Results and discussion
2.1. Chemistry
The general synthetic route to build the focused AChE-targeted
inhibitor library is illustrated in Scheme 1. Compound 9 could be
obtained by a sequential process involving alkylation of corre-
sponding pyridazinone (6) [32e34] and followed by reduction of
the nitro group under Fe/HOAc in refluxing EtOH. The final products
were obtained by 9 condensing the substituted piperidines in the
presence of triphosgene.
pound 12b displayed a potent activity with an IC50 of 0.188 mM,
which was about 9 folds more potent than the no-conjugation
extended compound 4.
In order to get a comprehensive understanding of the SAR,
docking study was performed. Crystal complex (code: 1EVE) of
donepezil and AChE protein was downloaded from Protein Data
Bank, in which the positively charged piperidine nitrogen in
donepezil achieves a caution- interaction with Phe330 and the
p
2.2. SAR study and docking study
terminal benzyl ring involves in pep stacking with aromatic Trp84.
Docking results showed that 12b may function as a bi-functional
AChE inhibitor with novel binding conformation, which the naph-
thyl occupies in the PAS pocket and the 4-diethyl amide piperidine
is located at the CAS near the bottom of the gorge. The carbonyl
oxygen on pyridazinone ring possibly takes part in hydrogen
bonding interaction with Phe288 and the 2-benzyl on pyridazinone
Structural inspections of the compounds in our HTS library
revealed that the terminal 4-diethyl amide piperidine in 4 may be
essential for activity. Firstly, we commenced with our work by
changing the substituents on the pyridazinone ring (Table 1).
Replacing the phenyl in 4 by a single hydrogen (10) caused a slight
loss in activity, which indicated that the phenyl might function as
a hydrophobic pharmacophore. As the AChE binding pocket is
a narrow hydrophobic gorge, a small hydrophobic methyl group
was added to the phenyl (11aec) for modulating the binding
involves in pep stacking with Tyr334 (Fig. 2). No direct hydrogen
bond interaction was observed in the urea motif of 12b, however,
just as donepezil complex, a water bridged hydrogen bonding
might occur in biological circumstances.
Scheme 1. Synthesis of analoguesa.

W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
97
Table 2
AChE inhibitory activity of 6-aniline substituted pyridazinones.
No.
Ar
IC50
(
mM)
No.
Ar
IC50 (mM)
13
3.28
15d
0.119
0.135
14
0.126
15e
15f
Fig. 2. Model of compound 12a bound to AChE. The naphthyl and 4-substituted
piperidine interact with PAS and CAS respectively.
15a
0.049
1.42
4.84
As shown in Fig. 3, docking results revealed that the naphthyl for
PAS binder in 12b not only acts as a hydrophobic group involving in
the van der Waals interactions with the protein, but also functions
15b
15c
16a
16b
16c
0.607
0.188
1.50
as a pep interaction element, which mainly works by the extended
aromatic ring B. Considering the hydrophobic effects induced by
the phenyl A in 12b and the methyl in 11c, a novel 6-aniline pyr-
idazinone scaffold was designed, in which the ring B is remained as
19.8
a
pe
p
interaction motif and ring A is broken by a single nitrogen
linker. In this new scaffold, stacking efficiency of ring B may
pep
also be elevated due to the increased rotation freedom.
Based on above analyses, 6-substituted aniline pyridazinones
were synthesized. As shown in Table 2, when the naphthyl (hy-
drophobic-
p motif) in 12b was replaced by a single aniline (nitro-
After the modification of the active compounds for PAS binding
site, we optimized the CAS binding motifs to synthesize compounds
17aef (Table 3). Cyclic analog 17a with the terminal morpholine
motif lost the activity totally. Among the acyclic amide series (17be
f), the inhibitory activity of the compounds strongly paralleled with
the hydrophobic effect of the substitutions. Among them, the N-
ethyl-N-isopropyl amide derivative 17e showed slightly more
potent than 15a. This phenomenon is consistent with the hydro-
phobic environment of the CAS binding pocket.
gen- motif, 13), the AChE inhibitory activity of 13 decreased
p
drastically (about 17 folds). However, the activity of 14 was restored
when the aniline was changed to more hydrophobic naphthalen-1-
amine, which indicated that the hydrophobic substitutions on the
aniline ring played a great part in binding affinity. Subsequently,
other analogs with different substituted anilines were synthesized
(15aef). The activity of compounds was decreased in the presence
of para substitutions (15c, f). The ortho substitutions significantly
increased the binding affinity probably due to a similar hydro-
phobic effect induced by ring A in 12b. In addition, a prevailing
‘Magic Methyl’ effect emerged in these pyridazinone compounds
[35], a single 2-methyl aniline derivative (15a) showed the prom-
2.3. Selectivity profile for AChE/BuChE
inent inhibitory potency with an IC50 of 0.049 mM. It was about 34
Moreover, the most potent and representative compounds were
selected for evaluation of AChE/BuChE selectivity profile. As shown
in Table 4, compared with the reported 3-amino-6-aryl pyridazine
series [29,30], 2,6-disubstituted pyridazin-3-one series displayed
about 200-fold or higher AChE/BuChE selectivity. For this scaffold,
AChE inhibitory activity of the compounds could be enhanced by
modifying PAS binding motif without affecting the BuChE affinity
by comparing 4 with 12b, or 13 with 15a. In the catalytic binding
pocket, increasing the hydrophobic groups of the amide (17dee)
lowered the IC50s for AChE accompanying with slight increasing
for the binding affinities of BuChE, However, the selectivity profiles
were still maintained.
and 4-fold more potent than 4 and 12b, respectively. Further
enlarging the steric hindrance to dimethyl, ethyl or isopropyl (16ae
c) decreased the activity.
Docking studies showed that 15a displays a similar binding
mode as 12b (Fig. 4A). Overlapping compounds 15a, 4 and 12b
(Fig. 4B) revealed that changing the phenyl in 4 with naphthyl (12b)
or adding a conjugated group (12c) made it possible for
pep
stacking with Trp279, which led to an increase in activity. In the
case of 15a, the 2-methyl aniline does act as a bi-functional group:
the aromatic phenyl stacks with Trp279 while the terminal methyl
fit within the PAS hydrophobic pocket perfectly.
Fig. 3. Designing strategy for aniline series.

98
W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
Table 3
SAR study at catalytic binding site.
No.
R
IC50
NA
(mM)
17a
17b
17c
7.60
0.473
17d
15a
17e
0.046
0.050
0.028
17f
0.116
300 mesh). 1H NMR and 13C NMR spectral data were recorded in
DMSO-d6, CD3OD or acetone-d6 on Varian Mercury 500, 400 or 300
NMR spectrometer and Chemical shifts (d) were reported in parts
per million (ppm), and the signals were described as brs (broad
singlet), d (doublet), dd (doublet of doublet), m (multiple), q
(quarter), s (singlet), and t (triplet). Coupling constants (J values)
were given in Hz. Low-resolution mass spectra (ESI) was obtained
using Agilent HPLC-MS (1260-6120B) and high-resolution mass
spectra (ESI) were obtained using Waters Q-Tof Ultima apparatus.
Fig. 4. (A) Model of compound 15a bound to AChE. The ortho-tolylamino and
4-substituted piperidine interact with PAS and CAS, respectively. (B) Overlap of 4
(magenta), 12b (yellow), and 15a (green). The naphthyl in 12b and ortho-methyl amine
in 15a function as pep stacking element and involve in PAS van der Waals interaction.
3. Conclusion
4.2. General procedures
In this report, a series of novel 2,6-disubstituted pyridazinone
derivatives for AChE inhibition was optimized. Under the SAR
development, high AChE affinity of the compounds was achieved
by optimizing different substituents on the pyridazinone ring,
without sacrificing the AChE/BuChE selectivity profile.
Docking study revealed that these pyridazinones might behave
as dual binding site inhibitors with novel binding conformation.
Utilizing this information, a delicate SAR study was performed at
PAS binding site and 6-ortho-tolylamino substitution was opti-
To a solution of pyridazinone derivative [32e34] (0.5 mmol) in
DMF (10 mL) was added 1-(chloromethyl) 3-nitrobenzene
(0.52 mmol) and Cs2CO3 (0.55 mmol), the resulting reaction mix-
ture was stirred at 40e50 ꢀC until no starting materials was
detected by TLC (about 3 h). The solvent was removed under
reduced pressure and the residue was dissolved in EtOAc (30 mL),
washed with brine (3 ꢁ 10 mL). The organic layer was dried over
anhydrous Na2SO4 and concentrated in vacuo. The crude product
was dissolved in 95% ethanol (50 mL) containing 10 mmol acetic
acid. Iron powder (2 mmol) was added and the resulting mixture
mized for involving in both pep stacking and “Magic Methyl” hy-
drophobic interaction. Moreover, rather than the prevailing N-
benzyl piperidine reported in donepezil, a novel hydrophobic 4-
substituted piperidine motif for catalytic pocket binder was dis-
closed, which also provided a new platform for designing AChE
inhibitor. Further biological evaluations of these pyridazinone se-
ries are ongoing.
Table 4
Selectivity profile of representative compounds for AChE versus BuChE.
No.
IC50
(
mM)
Ratio of IC50 (BuChE/AChE)
AChE
BuChE
4
12b
13
15a
17c
17d
17e
1.66
0.188
3.28
0.049
0.473
0.046
0.028
>40
>40
>40
>40
>40
10.0
5.50
>24
>212
>12
>816
>84
217
4. Experimental section
4.1. General information
Reagents were purified prior to use unless otherwise stated.
Column chromatography was carried out on silica gel (200e
196

W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
99
was stirred for 5 h. After cooled to room temperature, the reaction
mixture was filtered through celite and the filter cake was washed
with 95% ethanol (3 ꢁ 15 mL). The combined ethanol layers were
evaporated in vacuo and the residue was re-dissolved in ethyl ac-
etate (30 mL). The organic layer was washed with brine (3 ꢁ 10 mL)
and 2 M NaOH (10 mL) sequentially. The organic layer was dried
over anhydrous Na2SO4, evaporated in vacuo to afford the crude
2-aminobenzyl-6-substituted-pyridazin-3(2H)-ones, which were
used without further purification.
To a stirred solution of 2-aminobenzyl-6-substituted-pyridazin-
3(2H)-one and triphosgene (1 mmol) in dry dichloromethane
(5 mL) was added triethylamine (2 mmol) under nitrogen atmo-
sphere. A solution of the corresponding piperidine (1 mmol) in
dichloromethane (5 mL) was added 5e10 min later and the mixture
was stirred at room temperature overnight. The reaction mixture
was diluted with dichloromethane (15 mL) and washed with water
(3 ꢁ 20 mL). The organic phases were separated, dried over anhy-
drous Na2SO4 and concentrated in vacuo. The residue was purified
by column chromatography to afford the products.
502; HRMS(ESI) calcd for C29H35N5O3Na [M þ Na]þ 524.2638, found
524.2657.
4.2.4. N4,N4-Diethyl-N1-(3-((6-oxo-3-(p-tolyl)pyridazin-1(6H)-yl)
methyl)phenyl)piperidine-1,4-dicarboxamide(11b)
Yield: 61%: 1H NMR (300 MHz, acetone-d6)
d 8.02 (s, 1H), 7.90 (d,
J ¼ 9.7 Hz, 1H), 7.78 (d, J ¼ 8.3 Hz, 2H), 7.53 (d, J ¼ 10.8 Hz, 2H), 7.27
(d, J ¼ 8.0 Hz, 2H), 7.17 (t, J ¼ 7.8 Hz, 1H), 7.02 (d, J ¼ 7.4 Hz, 1H), 6.95
(d, J ¼ 9.7 Hz, 1H), 5.29 (s, 2H), 4.30e4.15 (m, 2H), 3.42 (q, J ¼ 7.2 Hz,
2H), 3.31 (q, J ¼ 7.0 Hz, 2H), 2.96e2.73 (m, 3H), 2.35 (s, 3H),1.71e1.58
(m, 4H), 1.17 (t, J ¼ 7.1 Hz, 3H), 1.02 (t, J ¼ 7.0 Hz, 3H); 13C NMR
(126 MHz, MeOD-d4) d 174.72, 160.21, 156.21, 145.44, 139.94, 139.53,
136.66, 131.53, 130.93, 129.26, 129.11, 128.29, 125.62, 122.50, 120.31,
120.13, 55.18 (eCH2ePhe), 43.28 (eNHCON(CH2CH2)2CHCOe),
41.79 (eCON(CH2CH3)2), 40.24 (eCON(CH2CH3)2), 38.28 (eNHCON
(CH2CH2)2CHCOe), 28.37 (eNHCON(CH2CH2)2CHCOe), 19.80 (e
NHePheCH3), 13.71 (eCON(CH2CH3)2), 11.77 (eCON(CH2CH3)2);
LCMS(ESI) m/z [M þ H]þ 502; HRMS(ESI) calcd for C29H35N5O3Na
[M þ Na]þ 524.2638, found 524.2622.
4.2.1. N4,N4-Diethyl-N1-(3-((6-oxo-3-phenylpyridazin-1(6H)-yl)
4.2.5. N4,N4-Diethyl-N1-(3-((6-oxo-3-(m-tolyl)pyridazin-1(6H)-yl)
methyl)phenyl)piperidine-1,4-dicarboxamide (4)
methyl)phenyl)piperidine-1,4-dicarboxamide (11c)
Yield: 81%: 1H NMR (300 MHz, acetone-d6)
d
8.03e7.87 (m, 4H),
Yield: 73%: 1H NMR (300 MHz, acetone-d6)
d 8.08 (s, 1H), 7.88 (d,
7.61e7.38 (m, 5H), 7.19 (t, J ¼ 7.9 Hz, 1H), 7.04 (d, J ¼ 7.7 Hz,1H), 6.99
(d, J ¼ 9.9 Hz,1H), 5.32 (s, 2H), 4.30e4.15 (m, 2H), 3.47e3.37 (m, 2H),
3.32 (d, J ¼ 6.8 Hz, 2H), 2.99e2.74 (m, 3H), 1.68 (s, 4H), 1.18 (t,
J ¼ 7.0 Hz, 3H), 1.03 (t, J ¼ 6.9 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
J ¼ 9.8 Hz, 1H), 7.72 (s, 1H), 7.65 (d, J ¼ 7.8 Hz, 1H), 7.61 (s, 1H), 7.51
(d, J ¼ 8.8 Hz, 1H), 7.32 (t, J ¼ 7.7 Hz, 1H), 7.22 (d, J ¼ 7.6 Hz, 1H), 7.17
(t, J ¼ 7.9 Hz, 1H), 7.01 (d, J ¼ 7.5 Hz,1H), 6.94 (d, J ¼ 9.7 Hz,1H), 5.29
(s, 2H), 4.28e4.15 (m, 2H), 3.47e3.28 (m, 4H), 3.00e2.71 (m, 3H),
2.37 (s, 3H), 1.75e1.55 (m, 4H), 1.22e1.10 (t, J ¼ 7.0 Hz, 3H), 1.01 (t,
d
174.67, 160.25, 156.20, 145.43, 139.91, 136.53, 134.31, 131.02, 129.41,
129.22, 128.51, 128.35, 125.74, 122.58, 120.41, 120.20, 55.33 (eCH2e
Phe), 43.31 (eNHCON(CH2CH2)2CHCOe), 41.84 (eCON(CH2CH3)2),
40.29 (eCON(CH2CH3)2), 38.32 (eNHCON(CH2CH2)2CHCOe), 28.39
(eNHCON(CH2CH2)2CHCOe), 13.85 (eCON(CH2CH3)2), 11.90 (e
CON(CH2CH3)2); HRMS(ESI): m/z [M þ H]þ 488; HRMS(ESI) calcd
for C28H33N5O3Na [M þ Na]þ 510.2481, found 510.2492.
J ¼ 7.0 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d 174.66, 160.15,
156.08, 145.40, 140.02, 138.35, 136.63, 134.19, 131.01, 129.91, 129.23,
128.40,128.33,126.24,122.88,122.43,120.22,120.00, 55.24 (eCH2e
Phe), 43.28 (eNHCON(CH2CH2)2CHCOe), 41.80 (eCON(CH2CH3)2),
40.24 (eCON(CH2CH3)2), 38.25 (eNHCON(CH2CH2)2CHCOe),
28.39 (eNHCON(CH2CH2)2CHCOe), 20.13 (eNHePheCH3e), 13.79
(eCON(CH2CH3)2), 11.86 (eCON(CH2CH3)2); LCMS(ESI) m/z
[M þ H]þ 502; HRMS(ESI) calcd for C29H35N5O3Na [M þ Na]þ
524.2638, found 524.2637.
4.2.2. N4,N4-Diethyl-N1-(3-((6-oxopyridazin-1(6H)-yl)methyl)
phenyl)piperidine-1,4-dicarboxamide (10)
Yield: 58%: 1H NMR (300 MHz, acetone-d6)
d 8.06 (s, 1H), 7.82
(dd, J ¼ 3.6, 1.4 Hz, 1H), 7.53 (d, J ¼ 8.2 Hz, 1H), 7.47 (s, 1H), 7.33 (dd,
J ¼ 9.5, 3.8 Hz, 1H), 7.16 (t, J ¼ 7.9 Hz, 1H), 6.94 (d, J ¼ 7.7 Hz, 1H),
6.87 (dd, J ¼ 9.5, 1.6 Hz, 1H), 5.21 (s, 2H), 4.29e4.15 (m, 2H), 3.43
(q, J ¼ 7.1 Hz, 2H), 3.32 (q, J ¼ 7.0 Hz, 2H), 2.98e2.77 (m, 3H), 1.73e
1.59 (m, 4H), 1.18 (t, J ¼ 7.1 Hz, 3H), 1.03 (t, J ¼ 7.0 Hz, 3H); 13C
4.2.6. N1-(3-((3-(3-Bromophenyl)-6-oxopyridazin-1(6H)-yl)
methyl)phenyl)-N4,N4-diethylpiperidine-1,4-dicarboxamide (11d)
Yield: 86%: 1H NMR (300 MHz, acetone-d6)
d 8.08 (s, 1H), 8.03e
7.93 (m, 2H), 7.90 (d, J ¼ 8.0 Hz, 1H), 7.60 (s, 2H), 7.51 (d, J ¼ 8.1 Hz,
1H), 7.42 (t, J ¼ 7.7 Hz, 1H), 7.18 (t, J ¼ 7.7 Hz, 1H), 7.00 (t, J ¼ 9.3 Hz,
2H), 5.31 (s, 2H), 4.28e4.15 (m, 2H), 3.42 (d, J ¼ 7.0 Hz, 2H), 3.31 (d,
J ¼ 7.2 Hz, 2H), 3.01e2.76 (m, 3H),1.67 (s, 4H), 1.17 (t, J ¼ 6.8 Hz, 3H),
NMR (125 MHz, MeOD-d4)
d 174.73, 161.04, 156.17, 139.92, 137.38,
136.56,132.36,129.08,128.25,122.32, 120.22, 120.04, 54.88 (eCH2e
Phe), 43.29 (eNHCON(CH2CH2)2CHCOe), 41.81 (eCON(CH2CH3)2),
40.25 (eCON(CH2CH3)2), 38.28 (eNHCON(CH2CH2)2CHCOe),
28.39 (eNHCON(CH2CH2)2CHCOe), 13.73 (eCON(CH2CH3)2), 11.78
(eCON(CH2CH3)2); LCMS(ESI) m/z 412 [M þ H]þ; HRMS(ESI) calcd
for C22H30N5O3 [M þ H]þ 412.2349, found 412.2331.
1.02 (t, J ¼ 6.9 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d 174.72,
160.14, 156.16, 143.77, 139.99, 136.47, 132.03, 130.76, 130.25, 129.50,
128.54, 128.33, 124.49, 122.54, 120.30, 120.12, 55.28 (eCH2ePhe),
43.28 (eNHCON(CH2CH2)2CHCOe), 41.80 (eCON(CH2CH3)2), 40.25
(eCON(CH2CH3)2), 38.27 (eNHCON(CH2CH2)2CHCOe), 28.38 (e
NHCON(CH2CH2)2CHCOe), 13.72 (eCON(CH2CH3)2), 11.78 (e
CON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 566; HRMS(ESI) calcd
for C28H32N5O3NaBr [M þ Na]þ 588.1586, found 588.1569.
4.2.3. Diethyl-N1-(3-((6-oxo-3-(o-tolyl)pyridazin-1(6H)-yl)methyl)
phenyl)piperidine-1,4-dicarboxamide (11a)
Yield: 69%: 1H NMR (300 MHz, acetone-d6)
d 8.01 (s, 1H), 7.53 (t,
J ¼ 8.3 Hz, 3H), 7.41 (d, J ¼ 7.1 Hz, 1H), 7.35e7.23 (m, 3H), 7.17 (t,
J ¼ 7.7 Hz, 1H), 7.03e6.92 (m, 2H), 5.27 (s, 2H), 4.31e4.16 (m, 2H),
3.42 (q, J ¼ 7.0 Hz, 2H), 3.34e3.26 (m, 2H), 2.87 (ddd, J ¼ 21.2, 14.9,
7.1 Hz, 3H), 2.32 (s, 3H),1.75e1.61 (m, 4H),1.17 (t, J ¼ 7.1 Hz, 3H),1.02
4.2.7. N1-(3-((3-(3-Chlorophenyl)-6-oxopyridazin-1(6H)-yl)
methyl)phenyl)-N4,N4-diethylpiperidine-1,4-dicarboxamide (11e)
Yield: 92%: 1H NMR (300 MHz, acetone-d6)
d 8.06 (s, 1H), 7.96 (d,
J ¼ 9.8 Hz, 2H), 7.85 (d, J ¼ 7.1 Hz,1H), 7.63 (s,1H), 7.55e7.43 (m, 3H),
7.18 (t, J ¼ 7.8 Hz, 1H), 7.02 (t, J ¼ 8.1 Hz, 2H), 5.32 (s, 2H), 4.30e4.19
(m, 2H), 3.50e3.25 (m, 4H), 3.01e2.75 (m, 3H), 1.78e1.60 (m, 4H),
1.18 (dd, J ¼ 8.3, 5.8 Hz, 3H), 1.03 (t, J ¼ 7.0 Hz, 3H); 13C NMR
(t, J ¼ 7.0 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d 174.72, 159.99,
156.17, 147.71, 139.97, 136.68, 135.94, 134.90, 134.25, 130.60, 128.91,
128.80, 128.71, 128.29, 125.72, 122.49, 120.40, 120.06, 55.02 (eCH2e
Phe), 43.30 (eNHCON(CH2CH2)2CHCOe), 41.80 (eCON(CH2CH3)2),
40.25 (eCON(CH2CH3)2), 38.29 (eNHCON(CH2CH2)2CHCOe), 28.39
(eNHCON(CH2CH2)2CHCOe), 19.20 (eNHePheCH3), 13.73 (e
CON(CH2CH3)2), 11.79 (eCON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ
(125 MHz, MeOD-d4) d 174.72, 160.16, 156.18, 143.90, 139.98, 136.47,
136.29, 134.54, 130.79, 130.03, 129.50, 129.05, 128.32, 125.61,
124.07, 122.55, 120.33, 120.13, 55.28 (eCH2ePhe), 43.27 (e
NHCON(CH2CH2)2CHCOe), 41.79 (eCON(CH2CH3)2), 40.24 (e

100
W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
CON(CH2CH3)2), 38.27 (eNHCON(CH2CH2)2CHCOe), 28.37 (e
NHCON(CH2CH2)2CHCOe), 13.71 (eCON(CH2CH3)2), 11.77 (e
CON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 522; HRMS(ESI) calcd
for C28H32N5O3NaCl [M þ Na]þ 544.2091, found 544.2084.
CON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 503; HRMS(ESI) calcd
for C28H34N6O3Na [M þ Na]þ 525.2590, found 525.2618.
4.2.12. N4,N4-Diethyl-N1-(3-((3-(naphthalen-1-ylamino)-6-
oxopyridazin-1(6H)-yl)methyl)phenyl) piperidine-1,4-
dicarboxamide (14)
4.2.8. N4,N4-Diethyl-N1-(3-((3-(naphthalen-2-yl)-6-oxopyridazin-
1(6H)-yl)methyl)phenyl) piperidine-1,4-dicarboxamide (12a)
Yield: 81%: 1H NMR (300 MHz, acetone-d6)
d
8.23 (d, J ¼ 8.8 Hz,
Yield: 88%: 1H NMR (300 MHz, acetone-d6)
d
8.39 (s, 1H), 8.25e
1H), 8.16 (s, 1H), 8.03 (s, 1H), 7.99e7.91 (m, 1H), 7.88 (d, J ¼ 4.7 Hz,
1H), 7.63e7.38 (m, 7H), 7.18 (t, J ¼ 7.8 Hz,1H), 6.99 (d, J ¼ 7.8 Hz,1H),
6.87 (d, J ¼ 9.8 Hz, 1H), 5.10 (s, 2H), 4.30e4.15 (m, 2H), 3.48e3.39
(m, 2H), 3.39e3.25 (m, 2H), 3.00e2.18 (m, 3H), 1.79e1.62 (m, 4H),
1.19 (t, J ¼ 6.8 Hz, 3H), 1.04 (t, J ¼ 7.1 Hz, 3H); 13C NMR (125 MHz,
7.70 (m, 6H), 7.68 (s, 1H), 7.53 (d, J ¼ 6.3 Hz, 3H), 7.19 (t, J ¼ 7.8 Hz,
1H), 7.06 (d, J ¼ 7.6 Hz, 1H), 6.98 (d, J ¼ 9.8 Hz, 1H), 5.33 (s, 2H),
4.30e4.15 (m, 2H), 3.44e3.29 (m, 4H), 2.98e2.73 (m, 3H), 1.68 (m,
4H), 1.23e1.09 (t, J ¼ 7.0 Hz, 3H), 1.02 (t, J ¼ 7.0 Hz, 3H); 13C NMR
(125 MHz, MeOD-d4)
d
174.69, 160.16, 156.18, 145.07, 140.00, 136.63,
MeOD-d4) d 174.84, 158.86, 156.34, 146.75, 139.88, 137.14, 135.47,
133.66, 133.14, 131.52, 130.89, 129.24, 128.33, 128.22, 128.20, 127.23,
126.61, 126.21, 125.33, 122.82, 122.57, 120.33, 120.09, 55.24 (eCH2e
Phe), 43.27 (eNHCON(CH2CH2)2CHCOe), 41.78 (eCON(CH2CH3)2),
40.23 (eCON(CH2CH3)2), 38.25 (eNHCON(CH2CH2)2CHCOe),
28.36 (eNHCON(CH2CH2)2CHCOe), 13.70 (eCON(CH2CH3)2), 11.77
(eCON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 538; HRMS(ESI) calcd
for C32H35N5O3Na [M þ Na]þ 560.2638, found 560.2643.
134.45, 130.31, 128.29, 128.10, 128.03, 127.27, 125.56, 125.40, 125.33,
123.40, 122.83, 121.69, 120.85, 120.16, 117.56, 54.11 (eCH2ePhe),
43.39 (eNHCON(CH2CH2)2CHCOe), 41.91 (eCON(CH2CH3)2), 40.36
(eCON(CH2CH3)2), 38.41 (eNHCON(CH2CH2)2CHCOe), 28.51 (e
NHCON(CH2CH2)2CHCOe), 13.82 (eCON(CH2CH3)2), 11.89 (e
CON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 553; HRMS(ESI) calcd
for C32H36N6O3Na [M þ Na]þ 575.2747, found 575.2739.
4.2.9. N4,N4-Diethyl-N1-(3-((3-(naphthalen-1-yl)-6-oxopyridazin-
4.2.13. N4,N4-Diethyl-N1-(3-((6-oxo-3-(o-tolylamino)pyridazin-
1(6H)-yl)methyl)phenyl) piperidine-1,4-dicarboxamide (12b)
1(6H)-yl)methyl)phenyl) piperidine-1,4-dicarboxamide (15a)
Yield: 76%: 1H NMR (300 MHz, acetone-d6)
d
8.19e7.87 (m, 4H),
Yield: 80%: 1H NMR (300 MHz, DMSO-d6)
d 8.51 (s, 1H), 7.93 (s,
7.72e7.46 (m, 7H), 7.22 (t, J ¼ 7.8 Hz,1H), 7.03 (q, J ¼ 8.7 Hz, 2H), 5.34
(s, 2H), 4.30e4.16 (m, 2H), 3.47e3.27 (m, 4H), 3.15e2.25 (m, 3H),
1.80e1.50 (m, 4H),1.23e1.12 (t, J ¼ 7.0 Hz, 3H),1.03 (t, J ¼ 7.0 Hz, 3H);
1H), 7.60 (d, J ¼ 9.0 Hz, 1H), 7.38 (m, 2H), 7.31e7.05 (m, 3H), 6.96e
6.79 (m, 3H), 4.20e4.12 (m 2H), 3.40e3.24 (m, 4H), 2.94e2.69 (m,
3H), 2.16 (s, 3H), 1.67e1.44 (m, 4H), 1.13 (t, J ¼ 7.0 Hz, 3H), 0.99 (t,
13C NMR (100 MHz, MeOD-d4)
d
174.74, 160.15, 156.21,
J ¼ 7.0 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d 174.73, 158.67,
147.00,140.08,136.73,134.90,133.93, 132.83,130.49,129.56,129.22,
128.46, 128.20, 127.13, 126.62, 125.93, 124.87, 124.70,122.86, 120.70,
120.26, 55.04 (eCH2ePhe), 43.35 (eNHCON(CH2CH2)2CHCOe),
41.88 (eCON(CH2CH3)2), 40.34 (eCON(CH2CH3)2), 38.36 (e
NHCON(CH2CH2)2CHCOe), 28.46 (eNHCON(CH2CH2)2CHCOe),
13.86 (eCON(CH2CH3)2), 11.91 (eCON(CH2CH3)2); LCMS(ESI) m/z
[M þ H]þ 538; HRMS(ESI) calcd for C32H35N5O3Na [M þ Na]þ
560.2638, found 560.2631.
156.21, 146.39, 139.77, 137.96, 137.05, 130.17, 130.02, 129.93, 128.15,
127.87, 125.84, 123.29, 122.65, 121.85, 120.75, 120.04, 53.87 (eCH2e
Phe), 43.28 (eNHCON(CH2CH2)2CHCOe), 41.80 (eCON(CH2CH3)2),
40.25 (eCON(CH2CH3)2), 38.30 (eNHCON(CH2CH2)2CHCOe), 28.40
(eNHCON(CH2CH2)2CHCOe), 16.77 (eNHePheCH3), 13.71 (e
CON(CH2CH3)2), 11.77 (eCON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ
517; HRMS(ESI) calcd for C29H36N6O3Na [M þ Na]þ 539.2747, found
539.2742.
4.2.10. N1-(3-((3-(3-Cyanophenyl)-6-oxopyridazin-1(6H)-yl)
4.2.14. N4,N4-Diethyl-N1-(3-((6-oxo-3-(m-tolylamino)pyridazin-
methyl)phenyl)-N4,N4-diethyl piperidine-1,4-dicarboxamide (12c)
1(6H)-yl)methyl)phenyl) piperidine-1,4-dicarboxamide (15b)
Yield: 79%: 1H NMR (300 MHz, acetone-d6)
d
8.31 (s, 1H), 8.23 (d,
Yield: 78%: 1H NMR (300 MHz, acetone-d6)
d 8.15 (s, 1H), 8.01 (s,
J ¼ 7.8 Hz,1H), 8.05 (s, 1H), 8.01 (s, 1H), 7.82 (d, J ¼ 7.6 Hz,1H), 7.70e
7.65 (m, 2H), 7.48 (d, J ¼ 7.9 Hz, 1H), 7.19 (t, J ¼ 7.8 Hz, 1H), 7.05 (d,
J ¼ 7.7 Hz, 1H), 7.00 (d, J ¼ 9.8 Hz, 1H), 4.30e4.17 (m, 2H), 3.43e3.25
(m, 4H), 3.00e2.80 (m, 3H),1.70e1.60 (m, 4H),1.12 (t, J ¼ 7.0 Hz, 3H),
1H), 7.56 (s, 2H), 7.40 (s,1H), 7.34 (d, J ¼ 7.9 Hz,1H), 7.26e7.10 (m, 3H),
7.07 (d, J ¼ 7.5 Hz,1H), 6.83 (d, J ¼ 9.8 Hz,1H), 6.74 (d, J ¼ 6.8 Hz,1H),
5.15 (s, 2H), 4.30e4.20 (m, 2H), 3.44 (t, J ¼ 7.0 Hz, 2H), 3.34 (q,
J ¼ 7.0 Hz, 2H), 3.00e2.92 (m, 3H), 2.28 (s, 3H),1.75e1.64 (m, 4H),1.20
(d, J ¼ 7.0 Hz, 3H), 1.05 (t, J ¼ 7.0 Hz, 3H); 13C NMR (125 MHz, MeOD-
1.03 (t, J ¼ 7.0 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d 174.71,160.04,
156.10, 143.14, 140.06, 136.39, 135.65, 132.42, 130.56, 130.07, 129.64,
129.27, 128.36, 122.58, 120.29, 120.01, 117.87, 112.71, 55.26 (eCH2e
Phe), 43.29 (eNHCON(CH2CH2)2CHCOe), 41.80 (eCON(CH2CH3)2),
40.25 (eCON(CH2CH3)2), 38.27 (eNHCON(CH2CH2)2CHCOe), 28.39
(eNHCON(CH2CH2)2CHCOe), 13.74 (eCON(CH2CH3)2), 11.80 (e
CON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 513; HRMS(ESI) calcd for
d4) d 174.66, 158.38, 156.14, 145.39, 140.29, 139.92, 138.00,
137.23, 129.97, 128.30, 128.19, 128.14, 122.79, 121.82, 120.80, 120.09,
118.22, 114.84, 53.96 (eCH2ePhe), 43.28 (eNHCON(CH2CH2)2
CHCOe), 41.81 (eCON(CH2CH3)2), 40.25 (eCON(CH2CH3)2), 38.26
(eNHCON(CH2CH2)2CHCOe), 28.41 (eNHCON(CH2CH2)2CH COe),
20.41 (eNHePheCH3), 13.80 (eCON(CH2CH3)2), 11.87 (e
CON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 517; HRMS(ESI) calcd for
C
29H32N6O3Na [M þ Na]þ 535.2434, found 535.2439.
C
29H36N6O3Na [M þ Na]þ 593.2747, found 593.2744.
4.2.11. N4,N4-Diethyl-N1-(3-((6-oxo-3-(phenylamino)pyridazin-
1(6H)-yl)methyl)phenyl) piperidine-1,4-dicarboxamide (13)
4.2.15. N4,N4-Diethyl-N1-(3-((6-oxo-3-(p-tolylamino)pyridazin-
Yield: 64%: 1H NMR (300 MHz, CD3OD-d4)
d
7.47 (d, J ¼ 8.2 Hz,
1(6H)-yl)methyl)phenyl) piperidine-1,4-dicarboxamide (15c)
2H), 7.41 (s, 1H), 7.33 (d, J ¼ 8.7 Hz, 1H), 7.25e7.07 (m, 4H), 7.08 (d,
J ¼ 7.6 Hz,1H), 6.92 (t, J ¼ 7.8 Hz, 2H), 5.20 (s, 2H), 4.30e4.15 (m, 2H),
3.50e3.30 (m, 4H), 3.05e2.72 (m, 3H), 1.80e1.64 (m, 4H), 1.23 (t,
J ¼ 7.0 Hz, 3H), 1.10 (t, J ¼ 7.1 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
Yield: 82%: 1H NMR (300 MHz, DMSO-d6)
d 8.88 (s, 1H), 8.49 (s,
1H), 7.45 (s, 1H), 7.40e7.32 (m, 3H), 7.20e7.13 (m, 2H), 7.02 (d,
J ¼ 8.5 Hz, 2H), 6.88e6.78 (m, 2H), 4.15e4.05 (m, 2H), 3.30e3.19 (m,
4H), 2.90e2.70 (m, 3H), 2.19 (s, 3H), 1.65e1.40 (m, 4H), 1.11 (t,
J ¼ 7.1 Hz, 3H), 0.97 (t, J ¼ 7.0 Hz, 3H); 13C NMR (100 MHz, MeOD-d4)
d
174.74,158.48,156.24,145.41,140.36,139.85,137.09,130.15,128.22,
128.17, 122.72, 121.03, 120.72, 120.05, 117.66, 101.92, 54.02 (eCH2e
Phe), 43.28 (eNHCON(CH2CH2)2CHCOe), 41.79 (eCON(CH2CH3)2),
40.24 (eCON(CH2CH3)2), 38.30 (eNHCON(CH2CH2)2CHCOe), 28.38
(eNHCON(CH2CH2)2CHCOe), 13.69 (eCON(CH2CH3)2), 11.75 (e
d 174.79,158.51,156.32,145.63,139.90,137.90,137.17,130.55,130.06,
128.74, 128.28, 128.22, 122.79, 120.78, 120.11, 117.87, 54.12 (eCH2e
Phe), 43.36 (eNHCON(CH2CH2)2CHCOe), 41.86 (eCON(CH2CH3)2),
40.31(eCON(CH2CH3)2), 38.36 (eNHCON(CH2CH2)2CHCOe), 28.46

W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
101
(eNHCON(CH2CH2)2CHCOe), 19.40 (eNHePheCH3), 13.77 (e
CON(CH2CH3)2), 11.83 (eCON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ
517; HRMS(ESI) calcd for C29H36N6O3Na [M þ Na]þ 593.2747, found
593.2745.
3.10e2.25 (m, 3H), 2.14 (s, 6H), 1.77e1.63 (m, 4H), 1.19 (t, J ¼ 7.0 Hz,
3H), 1.04 (t, J ¼ 7.0 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d 174.74,
158.58, 156.17, 147.34, 139.60, 136.96, 135.97, 135.60, 130.43, 128.02,
127.62, 126.56, 125.95, 122.47, 120.84, 120.01, 53.60 (eCH2ePhe),
43.28 (eNHCON(CH2CH2)2CHCOe), 41.81 (eCON(CH2CH3)2), 40.25
(eCON(CH2CH3)2), 38.32 (eNHCON(CH2CH2)2CHCOe), 28.43 (e
NHCON(CH2CH2)2CHCOe), 17.07, 13.72 (eCON(CH2CH3)2), 11.78 (e
CON(CH2CH3)2); HRMS(ESI) m/z [M þ H]þ 531; HRMS(ESI) calcd
for C30H38N6O3Na [M þ Na]þ 553.2903, found 553.2876.
4.2.16. N4,N4-Diethyl-N1-(3-((6-oxo-3-((2-(trifluoromethyl)phenyl)
amino)pyridazin-1(6H)-yl)methyl)phenyl)piperidine-1,4-
dicarboxamide (15d)
Yield: 75%: 1H NMR (300 MHz, acetone-d6)
d 8.06 (s, 1H), 7.91 (d,
J ¼ 8.4 Hz, 1H), 7.64 (d, J ¼ 7.9 Hz, 1H), 7.61e7.53 (m, 2H), 7.50 (d,
J ¼ 8.1 Hz, 1H), 7.39 (d, J ¼ 9.8 Hz, 2H), 7.25e7.10 (m, 2H), 6.97 (d,
J ¼ 7.6 Hz, 1H), 6.88 (d, J ¼ 9.8 Hz, 1H), 5.07 (s, 2H), 4.30e4.15 (m,
2H), 3.50e3.40 (m, 2H), 3.40e3.25 (m, 2H), 2.90e2.77 (m, 3H),
1.78e1.63 (m, 4H), 1.23e1.14 (t, J ¼ 7.0 Hz, 3H), 1.04 (t, J ¼ 7.0 Hz,
4.2.20. N4,N4-Diethyl-N1-(3-((3-((2-ethylphenyl)amino)-6-
oxopyridazin-1(6H)-yl)methyl) phenyl)piperidine-1,4-
dicarboxamide (16b)
Yield: 70%: 1H NMR (300 MHz, acetone-d6)
d 8.07 (s, 1H), 7.68 (d,
3H); 13C NMR (125 MHz, MeOD-d4)
d
174.68, 158.74, 156.12, 145.73,
J ¼ 8.0 Hz,1H), 7.52 (d, J ¼ 8.8 Hz, 2H), 7.36 (s, 1H), 7.26 (t, J ¼ 6.6 Hz,
1H), 7.21e7.08 (m, 3H), 6.99 (m, 2H), 6.85e6.76 (m,1H), 5.06 (s, 2H),
4.24 (m, 2H), 3.50e3.28 (m, 4H), 3.10e2.28 (m, 3H), 2.66 (q,
J ¼ 7.5 Hz, 2H), 1.78e1.62 (m, 4H), 1.24e1.09 (m, 6H), 1.15e1.10 (m,
139.89, 137.65, 136.99, 132.35, 130.67, 128.23, 127.90, 125.92, 125.88,
125.10, 123.35, 122.67, 121.71, 121.48, 120.76, 120.03, 53.98 (eCH2e
Phe), 43.30 (eNHCON(CH2CH2)2CHCOe), 41.82 (eCON(CH2CH3)2),
40.25 (eCON(CH2CH3)2), 38.29 (eNHCON(CH2CH2)2CHCOe),
28.44 (eNHCON(CH2CH2)2CHCOe), 13.80 (eCON(CH2CH3)2), 11.86
(eCON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 571; HRMS(ESI) calcd
for C29H33N6O3NaF3 [M þ Na]þ 593.2464, found 593.2485.
3H); 13C NMR (125 MHz, MeOD-d4)
d 174.73, 158.68, 156.21,
146.84, 139.75, 137.22, 137.06, 136.55, 130.19, 128.25, 128.13,
127.68, 125.83, 123.96, 123.11, 122.64, 120.75, 120.04, 53.86 (eCH2e
Phe), 43.28 (eNHCON(CH2CH2)2CHCOe), 41.80 (eCON(CH2CH3)2),
40.25 (eCON(CH2CH3)2), 38.31 (eNHCON(CH2CH2)2CHCOe),
28.41 (eNHCON(CH2CH2)2CHCOe), 23.76 (eNHePheCH2CH3),
13.71 (eCON(CH2CH3)2), 13.16 (eNHePheCH2CH3), 11.78 (e
CON(CH2CH3)2); HRMS(ESI) m/z [M þ H]þ 531; HRMS(ESI) calcd
for C30H38N6O3Na [M þ Na]þ 553.2903, found 553.2903.
4.2.17. N4,N4-Diethyl-N1-(3-((6-oxo-3-((3-(trifluoromethyl)phenyl)
amino)pyridazin-1(6H)-yl) methyl)phenyl)piperidine-1,4-
dicarboxamide (15e)
Yield: 74%: 1H NMR (400 MHz, CD3OD)
d 7.93 (s, 1H), 7.57 (d,
J ¼ 9.2 Hz, 1H), 7.46 (s, 1H), 7.32 (t, J ¼ 8.0 Hz, 2H), 7.21 (t, J ¼ 7.8 Hz,
1H), 7.12 (d, J ¼ 7.7 Hz,1H), 7.09 (d, J ¼ 7.6 Hz,1H), 7.00 (d, J ¼ 9.7 Hz,
1H), 6.76 (d, J ¼ 9.7 Hz,1H), 5.12 (s, 2H), 4.18 (d, J ¼ 13.2 Hz, 2H), 3.45e
3.34 (m, 2H), 3.30 (t, J ¼ 7.1 Hz, 2H), 2.99e2.82 (m, 2H), 2.82e2.73 (m,
1H), 1.69 (dd, J ¼ 19.6, 8.4 Hz, 4H), 1.17 (t, J ¼ 7.1 Hz, 3H), 1.05 (t,
4.2.21. N4,N4-Diethyl-N1-(3-((3-((2-isopropylphenyl)amino)-6-
oxopyridazin-1(6H)-yl)methyl) phenyl)piperidine-1,4-
dicarboxamide (16c)
Yield: 89%: 1H NMR (300 MHz, acetone-d6)
d 8.10 (s, 1H), 7.49 (m,
J ¼ 7.1 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d
174.63,158.28,156.16,
4H), 7.27 (d, J ¼ 7.4 Hz, 1H), 7.22 (d, J ¼ 9.8 Hz,1H), 7.18e7.01 (m, 3H),
6.91 (d, J ¼ 7.5 Hz, 1H), 6.79 (d, J ¼ 9.8 Hz,1H), 5.03 (s, 2H), 4.30e4.15
(m, 2H), 3.50e3.25 (m, 5H), 2.99e2.73 (m, 3H), 1.75e1.61 (m, 4H),
1.25e1.05 (m, 9H), 1.02 (t, J ¼ 7.0 Hz, 3H); 13C NMR (125 MHz, MeOD-
144.83, 141.02, 139.97, 137.01, 130.45, 129.02, 128.36, 127.95, 125.36,
123.20, 123.03, 121.08, 120.67, 120.38, 117.01, 113.70, 54.15 (eCH2e
Phe), 43.31 (eNHCON(CH2CH2)2CHCOe), 41.80 (eCON(CH2CH3)2),
40.24 (eCON(CH2CH3)2), 38.26 (eNHCON(CH2CH2)2CHCOe), 28.40
(eNHCON(CH2CH2)2CHCOe), 13.80 (eCON(CH2CH3)2), 11.87 (e
CON(CH2CH3)2); LCMS(ESI) m/z [M þ H]þ 571; HRMS(ESI) calcd for
d4)
d 174.73, 158.71, 156.21, 147.50, 142.44, 139.71, 137.06, 136.38,
130.20, 128.11, 127.46, 125.67, 125.31, 124.83, 124.61, 122.46, 120.59,
120.00, 53.92 (eCH2ePhe), 43.27 (eNHCON(CH2CH2)2CHCOe),
41.80 (eCON(CH2CH3)2), 40.24 (eCON(CH2CH3)2), 38.30 (e
NHCON(CH2CH2)2CHCOe), 28.40 (eNHCON(CH2CH2)2CHCOe), 27.21
(PheCH(CH3)2e), 22.22 (PheCH(CH3)2e), 13.71 (eCON(CH2 CH3)2),
11.77 (eCON(CH2CH3)2); HRMS(ESI) m/z [M þ H]þ 545; HRMS(ESI)
calcd for C31H40N6O3Na [M þ H]þ 567.3060, found 567.3058.
C
29H33N6O3NaF3 [M þ Na]þ 593.2464, found 593.2449.
4.2.18. N4,N4-Diethyl-N1-(3-((6-oxo-3-((4-(trifluoromethyl)phenyl)
amino)pyridazin-1(6H)-yl) methyl)phenyl)piperidine-1,4-
dicarboxamide (15f)
Yield: 58%: 1H NMR (300 MHz, CD3OD-d4)
d
7.62 (d, J ¼ 8.6 Hz,
2H), 7.54e7.45 (m, 3H), 7.35e7.29 (m,1H), 7.26 (t, J ¼ 7.7 Hz,1H), 7.18
(d, J ¼ 9.7 Hz,1H), 7.09 (d, J ¼ 7.2 Hz,1H), 6.94 (d, J ¼ 9.7 Hz,1H), 4.25e
4.15 (m, 2H), 3.50e3.31 (m, 4H), 3.32e2.78 (m, 3H), 1.77e1.66 (m,
3H),1.23 (t, J ¼ 7.1 Hz, 3H),1.09 (t, J ¼ 7.1 Hz, 3H); 13C NMR (126 MHz,
4.2.22. 4-(Morpholine-4-carbonyl)-N-(3-((6-oxo-3-(o-tolylamino)
pyridazin-1(6H)-yl)methyl) phenyl)piperidine-1-carboxamide (17a)
Yield: 89%: 1H NMR (300 MHz, acetone-d6)
d 7.65 (s, 1H), 7.37 (d,
J ¼ 7.7 Hz, 1H), 7.20e7.15 (d, J ¼ 9.2 Hz, 2H), 6.92 (d, J ¼ 9.6 Hz, 2H),
6.85e6.70 (m, 3H), 6.64e6.51 (m, 2H), 6.46 (d, J ¼ 9.5 Hz,1H), 3.90e
3.75 (m, 2H), 3.30e3.20 (s, 4H), 3.19e3.08 (m, 2H), 2.57e2.48 (m,
5H), 1.88 (s, 3H), 1.75e1.60 (m, 4H); 13C NMR (126 MHz, MeOD-d4)
DMSO-d6)
d 173.40, 157.48, 155.21, 155.14, 144.53, 143.87, 143.78,
141.31, 141.21, 137.65, 131.83, 128.75, 128.37, 128.30, 126.40,
126.14, 123.99, 122.11, 120.87, 120.61, 119.99, 119.89, 119.01, 118.91,
117.30, 117.24, 53.73 (eCH2ePhe), 43.71 (eNHCON(CH2CH2)2
CHCOe), 41.48 (eCON(CH2CH3)2), 39.76 (eCON(CH2CH3)2), 37.86
(eNHCON(CH2CH2)2CHCOe), 28.93 (eNHCON(CH2CH2)2CHCOe),
15.34 (eCON(CH2CH3)2), 13.39 (eCON(CH2CH3)2); LCMS(ESI) m/z
[M þ H]þ 571; HRMS(ESI) calcd for C29H33N6O3NaF3 [M þ Na]þ
593.2464, found 593.2482.
d
174.05,158.78,156.32,146.49,139.86,138.07,137.17,130.29,130.13,
130.03, 128.28, 127.99, 125.95, 123.39, 122.78, 121.95, 120.89, 120.16,
66.61 (CON(CH2CH2)2O), 66.41(CON(CH2CH2)2O), 53.99 (eCH2e
Phe), 45.83 (CON(CH2CH2)2O), 43.35 (eNHCON(CH2CH2)2CHCOe),
42.05 (CON(CH2CH2)2 O), 37.75 (eNHCON(CH2CH2)2CHCOe),
28.21 (eNHCON(CH2CH2)2CHCOe); LCMS(ESI) m/z [M þ H]þ 531;
HRMS(ESI) calcd for C29H34N6O4Na [M þ Na]þ 553.2539, found
553.2514.
4.2.19. N1-(3-((3-((2,6-Dimethylphenyl)amino)-6-oxopyridazin-
1(6H)-yl)methyl)phenyl)-N4,N4-diethylpiperidine-1,4-
dicarboxamide (16a)
4.2.23. N4,N4-Dimethyl-N1-(3-((6-oxo-3-(o-tolylamino)pyridazin-
Yield: 76%: 1H NMR (300 MHz, acetone-d6)
d
8.01 (s, 1H), 7.51 (d,
1(6H)-yl)methyl)phenyl) piperidine-1,4-dicarboxamide(17b)
J ¼ 9.1 Hz, 1H), 7.31 (d, J ¼ 7.0 Hz, 2H), 7.16e7.02 (m, 5H), 6.79 (d,
Yield: 93%: 1H NMR (300 MHz, acetone-d6)
d
8.04 (s, 1H), 7.72 (d,
J ¼ 9.7 Hz, 2H), 4.92 (s, 2H), 4.3e4.15 (m, 2H), 3.51e3.31 (m, 4H),
J ¼ 8.7 Hz, 1H), 7.51 (m, 2H), 7.33 (s, 1H), 7.28 (d, J ¼ 9.8 Hz, 1H),

102
W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
7.21e7.09 (m, 3H), 7.00e6.70 (m, 2H), 6.82 (d, J ¼ 9.8 Hz, 1H), 5.07
(s, 2H), 4.30e4.15 (m, 2H), 3.10 (s, 3H), 2.92e2.80 (m, 3H), 2.86 (s,
3H), 2.24 (s, 3H), 1.76e1.54 (m, 4H); 13C NMR (125 MHz, MeOD-d4)
38.43 (eNHCON(CH2CH2)2 CHCOe), 37.02 (eCON(CH2CH3)
CH(CH3)2), 35.27 (eCON(CH2CH3)CH(CH3)2), 28.52 (eNHCO
N(CH2CH2)2CHCOe), 28.50 (eNHCON(CH2CH2)2 CHCOe), 20.27 (e
CON(CH2CH3)CH(CH3)2), 19.13 (eCON(CH2CH3)CH(CH3)2), 16.87 (e
d
175.45, 158.78, 156.32, 146.49, 139.89, 138.07, 137.17, 130.29,
130.14, 130.04, 128.27, 128.00, 125.95, 123.40, 122.75, 121.96, 120.88,
120.14, 53.98 (eCH2ePhe), 43.40 (eNHCON(CH2CH2)2CHCOe),
38.25 (eNHCON(CH2CH2)2CHCOe), 36.19 (eCON(CH3)2), 34.65 (e
CON(CH3)2), 28.01 (eNHCON(CH2CH2)2CHCOe), 16.90; LCMS(ESI)
m/z [M þ H]þ 489; HRMS(ESI) calcd for C27H32N6O3Na [M þ Na]þ
511.2434, found 511.2453.
NHePheCH3), 16.17
(eCON(CH2CH3)CH(CH3)2), 13.71
(e
CON(CH2CH3)CH(CH3)2); LCMS(ESI) m/z [M þ H]þ 531; HRMS(ESI)
calcd for C30H38N6O3Na [M þ Na]þ 553.2903, found 553.2926.
4.2.27. N4,N4-Diisopropyl-N1-(3-((6-oxo-3-(o-tolylamino)
pyridazin-1(6H)-yl)methyl) phenyl)piperidine-1,4-dicarboxamide
(17f)
4.2.24. N4-Ethyl-N4-methyl-N1-(3-((6-oxo-3-(o-tolylamino)
pyridazin-1(6H)-yl)methyl) phenyl)piperidine-1,4-
dicarboxamide(17c)
Yield: 62%: 1H NMR (300 MHz, acetone-d6)
d 7.97 (s,1H), 7.77e7.66
(m, 1H), 7.51 (m, 2H), 7.34e7.21 (m, 2H), 7.21e7.10 (m, 3H), 6.99e6.70
(m, 2H), 6.81 (d, J ¼ 9.8 Hz,1H), 5.06 (s, 2H), 4.25e4.11 (m, 4H), 3.55 (s,
1H), 3.01e2.74 (m, 3H), 2.23 (s, 3H), 1.74e1.62 (m, 4H), 1.36e1.19 (m,
Yield: 75%: 1H NMR (300 MHz, CD3OD)
d
7.48 (d, J ¼ 8.0 Hz, 1H),
7.31 (m, 2H), 7.22 (t, J ¼ 7.9 Hz, 2H), 7.18e7.05 (m, 2H), 6.96 (t,
J ¼ 7.8 Hz, 2H), 6.91e6.82 (m, 1H), 5.09 (s, 2H), 4.25e4.10 (m, 2H),
3.52e3.27 (m, 2H), 3.08 (s, 1.5H), 3.03e2.78 (m, 4.5H), 2.18 (s, 3H),
12H); 13C NMR (125 MHz, MeOD-d4)
d 158.80, 156.36, 146.51,
139.88, 138.07, 137.17, 130.29, 130.12, 130.08, 128.25, 127.97, 125.94,
123.41, 122.76, 122.00, 120.85, 120.16, 53.97 (eCH2ePhe), 45.77 (e
CON(CH(CH3)2)2), 43.43 (eNHCON(CH2CH2)2CHCOe), 39.84 (e
1.80e1.58 (m, 4H),1.21 (t, J ¼ 7.1 Hz,1.5H),1.08 (t, J ¼ 7.1 Hz, 1.5H); 13
C
NMR (125 MHz, MeOD-d4)
d
175.27, 174.89, 158.78, 156.32, 146.48,
NHCON(CH2CH2)2CHCOe),
28.56
(eNHCON(CH2CH2)2CHCOe),
139.89, 138.08, 137.18, 130.29, 130.14, 130.01, 128.27, 127.98,
125.96, 123.39, 122.76, 121.94, 120.86, 120.15, 53.98 (eCH2ePhe),
44.14 (eCON(CH3)CH2CH3), 43.41 (eNHCON(CH2CH2)2CHCOe),
43.38 (eNHCON(CH2CH2)2CHCOe), 42.53 (eCON(CH3)CH2CH3),
38.45 (eNHCON(CH2CH2)2CHCOe), 38.20 (eNHCON(CH2CH2)2
CHCOe), 33.79 (eCON(CH3)CH2CH3), 32.17 (eCON(CH3)CH2CH3),
28.54 (eNHCON(CH2CH2)2CHCOe), 27.95 (eNHCON(CH2CH2)2
CHCOe), 16.89, 13.02 (eCON(CH3)CH2CH3), 11.04 (eCON(CH3)
CH2CH3); LCMS(ESI) m/z [M þ H]þ 503; HRMS(ESI) calcd for
19.52 (eCON(CH(CH3)2)2), 16.86; LCMS(ESI) m/z [M þ H]þ 545;
HRMS(ESI) calcd for C31H40N6O3Na [M þ Na]þ 567.3060, found
567.3073.
5. Materials and methods
5.1. Biological assays
Cholinesterase (ChE) activity was evaluated using modified
Ellman’s spectrophotometric method [36]. Individual compounds
were dissolved in dimethyl sulfoxide (DMSO) to a concentration of
10 mM and diluted to appropriate concentrations in double-
distilled water. For in vitro tests of inhibition, 4 mL reaction mix-
tures consisting 0.1 mL of test compound, selective substrate
[0.6 mL acetylthiocholine iodide for AChE (2 mM) or 0.8 mL S-
butyrylthiocholine iodide for BuChE (2 mM)], 1 mL of phosphate
buffered solution (0.1 mM), and 0.1 mL of enzyme (homogenate of
rat cerebral cortex for AChE, rat serum for BuChE) were incubated at
37 ꢀC for 8 min, and the reaction was terminated with 1 mL of 3%
(w/v) sodium dodecylsulfate (SDS). Finally, 1 mL of 0.2% (w/v) 5,50-
Dithiobis (2-nitrobenzoic acid) (DTNB) was added, and the yellow
anion, 5-thio-2-nitrobenzate, was measured at 440 nm. All samples
were assayed in duplicate.
C
28H34N6O3Na [M þ Na]þ 525.2590, found 525.2600.
4.2.25. N4-Isopropyl-N4-methyl-N1-(3-((6-oxo-3-(o-tolylamino)
pyridazin-1(6H)-yl)methyl) phenyl)piperidine-1,4-dicarboxamide
(17d)
Yield: 68%: 1H NMR (300 MHz, CD3OD)
d
7.49 (d, J ¼ 8.0 Hz, 1H),
7.33e7.27 (m, 2H), 7.27e7.19 (m, 2H), 7.19e7.06 (m, 2H), 6.97 (t,
J ¼ 7.7 Hz, 2H), 6.88 (d, J ¼ 9.7 Hz, 1H), 5.10 (s, 2H), 4.80e4.71 (m,
0.5H), 4.39e4.24 (m, 0.5H), 4.25e4.12 (m, 2H), 3.04e2.81 (m, 4.5H),
2.77 (s, 1.5H), 2.19 (s, 3H), 1.82e1.59 (m, 4H), 1.24 (d, J ¼ 6.6 Hz, 3H),
1.10 (d, J ¼ 6.8 Hz, 3H); 13C NMR (125 MHz, MeOD-d4)
d 174.92,
174.88, 158.78, 156.33, 146.49, 139.88, 138.07, 137.17, 130.28,
130.13, 130.04, 128.26, 127.97, 125.95, 123.40, 122.76, 121.97,
120.87, 120.16, 53.97 (eCH2ePhe), 44.38 (eCON(CH3)CH(CH3)2),
43.44 (eNHCON(CH2CH2)2CHCOe), 43.40 (eNHCON (CH2CH2)2CH
COe), 39.00 (eNHCON(CH2CH2)2CHCOe), 38.43 (eNHCON(CH2
CH2)2 CHCOe), 28.65 (eNHCON(CH2CH2)2CHCOe), 27.99 (eNHCON
(CH2CH2)2CHCOe), 27.24 (eCO N(CH3)CH(CH3)2), 25.43 (eCON
(CH3)CH(CH3)2), 19.49 (eCON(CH3)CH(CH3)2), 18.10 (eCON(CH3)
CH(CH3)2), 16.88 (eNHePheCH3); LCMS(ESI) m/z [M þ H]þ 517;
HRMS(ESI) calcd for C29H36N6O3Na [M þ Na]þ 539.2747, found
539.2733.
5.2. Docking
The crystal structure of donepezileAChE complex (code ID:
1EVE) was downloaded from the Protein Data Bank. Further
preparation of the protein included deleting the waters, addition of
hydrogen atoms and applying CHARMm forcefield. The 3D Struc-
tures of 4, 12b and 15a were built and performed geometry opti-
mization by molecular mechanics.
Docking studies were performed using the CDOCKER protocol of
Discovery Studio 2.1 program. The binding sphere was generated at
the center of the donepezil with a radius of 11.5 Å. Then the ligand
donepezil was deleted and the docking results were obtained using
the default settings except the value of random conformations was
set to 300 and the value of top hits was set to 20. The docking re-
sults were analyzed using Discovery Studio 3.5 Visualizer.
4.2.26. N4-Ethyl-N4-isopropyl-N1-(3-((6-oxo-3-(o-tolylamino)
pyridazin-1(6H)-yl)methyl) phenyl)piperidine-1,4-
dicarboxamide(17e)
Yield: 55%: 1H NMR (300 MHz, CD3OD)
d
7.49 (d, J ¼ 8.0 Hz, 1H),
7.33 (d, J ¼ 7.8 Hz, 2H), 7.29e7.19 (m, 2H), 7.19e7.05 (m, 2H), 6.98 (d,
J ¼ 7.6 Hz, 2H), 6.88 (d, J ¼ 9.7 Hz, 1H), 5.10 (s, 2H), 4.65e4.50 (m,
0.5H), 4.30e4.12 (m, 2.5H), 3.43e3.20 (m, 2H), 3.10e2.75 (m, 3H),
2.19 (s, 3H),1.90e1.75 (m, 4H),1.28e1.08 (m, 9H); 13C NMR (125 MHz,
MeOD-d4)
d
175.20, 174.34, 158.63, 156.15, 146.35, 139.79, 137.97,
Acknowledgments
137.03, 130.16, 130.06, 129.80, 128.19, 127.93, 125.87, 123.24, 122.62,
121.74, 120.81, 120.03, 53.98 (eCH2ePhe), 45.73 (eCON(CH3)
This work was supported by grant from National Science &
Technology Major Project “Key New Drug Creation and Manu-
facturing Program” (2012ZX09301001-001).
CH(CH3)2),
43.32
(eNHCON(CH2CH2)2CHCOe),
42.02
(e
NHCON(CH2CH2)2CHCOe), 39.25 (eNHCON(CH2CH2)2 CHCOe),

W. Xing et al. / European Journal of Medicinal Chemistry 63 (2013) 95e103
103
[18] A. Samadi, C. de los Ríos, I. Bolea, M. Chioua, I. Iriepa, I. Moraleda, M. Bartolini,
V. Andrisano, E. Gálvez, C. Valderas, M. Unzeta, J. Marco-Contelles, Multi-
potent MAO and cholinesterase inhibitors for the treatment of Alzheimer’s
disease: synthesis, pharmacological analysis and molecular modeling of het-
erocyclic substituted alkyl and cycloalkyl propargyl amine, Eur. J. Med. Chem.
52 (2012) 251e262.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.ejmech.2013.01.056.
[19] Y.P. Pang, P. Quiram, T. Jelacic, F. Hong, S. Brimijoin, Highly potent, selective,
and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase,
J. Biol. Chem. 271 (1996) 23646e23649.
[20] F. Leonetti, M. Catto, O. Nicolotti, L. Pisani, A. Cappa, A. Stefanachi, A. Carotti,
Homo- and hetero-bivalent edrophonium-like ammonium salts as highly
potent, dual binding site AChE inhibitors, Bioorg. Med. Chem. 16 (2008)
7450e7456.
[21] X. He, S. Feng, Z.F. Wang, Y. Shi, S. Zheng, Y. Xia, H. Jiang, X.-C. Tang, D. Bai,
Study on dual-site inhibitors of acetylcholinesterase: highly potent de-
rivatives of bis- and bifunctional huperzine B, Bioorg. Med. Chem. 15 (2007)
1394e1408.
[22] S. Gemma, E. Gabellieri, P. Huleatt, C. Fattorusso, M. Borriello, B. Catalanotti,
S. Butini, A.M. De, E. Novellino, V. Nacci, T. Belinskaya, A. Saxena, G. Campiani,
Discovery of huperzine a-tacrine hybrids as potent inhibitors of human cho-
linesterases targeting their midgorge recognition sites, J. Med. Chem. 49
(2006) 3421e3425.
[23] S. Feng, Z. Wang, X. He, S. Zheng, Y. Xia, H. Jiang, X. Tang, D. Bai, Bis-huperzine
B: highly potent and selective acetylcholinesterase inhibitors, J. Med. Chem.
48 (2005) 655e657.
[24] P.R. Carlier, Y.F. Han, E.S.H. Chow, C.P.L. Li, H. Wang, T.X. Lieu, H.S. Wong,
Y.P. Pang, Evaluation of short-tether bis-THA acetylcholinesterase inhibitors.
A further test of the dual binding site hypothesis, Bioorg. Med. Chem. 7 (1999)
351e357.
References
[1] G. Zimmerman, H. Soreq, Termination and beyond: acetylcholinesterase as
a modulator of synaptic transmission, Cell. Tissue Res. 326 (2006) 655e669.
[2] H.T. Xiao, J. Peng, Y. Liang, J. Yang, X. Bai, X.Y. Hao, F.-M. Yang, Q.Y. Sun,
Acetylcholinesterase inhibitors from Corydalis yanhusuo, Nat. Prod. Res. 25
(2011) 1418e1422.
[3] S.F. Tsai, S.S. Lee, Characterization of acetylcholinesterase inhibitory constit-
uents from annona glabra assisted by HPLC microfractionation, J. Nat. Prod. 73
(2010) 1632e1635.
[4] L. Huang, Z. Luo, F. He, A. Shi, F. Qin, X. Li, Berberine derivatives, with
substituted amino groups linked at the 9-position, as inhibitors of ace-
tylcholinesterase/butyrylcholinesterase, Bioorg. Med. Chem. Lett. 20 (2010)
6649e6652.
[5] L. Huang, A. Shi, F. He, X. Li, Synthesis, biological evaluation, and molecular
modeling of berberine derivatives as potent acetylcholinesterase inhibitors,
Bioorg. Med. Chem. 18 (2010) 1244e1251.
[6] W.J. Shan, L. Huang, Q. Zhou, F.C. Meng, X.-S. Li, Synthesis, biological evalua-
tion of 9-N-substituted berberine derivatives as multi-functional agents of
antioxidant, inhibitors of acetylcholinesterase, butyrylcholinesterase and
amyloid-b aggregation, Eur. J. Med. Chem. 46 (2011) 5885e5893.
[25] A. Badia, J.E. Banos, P. Camps, J. Contreras, D.M. Gorbig, D. Munoz-Torrero,
M. Simon, N.M. Vivas, Synthesis and evaluation of tacrine-huperzine A hybrids
as acetylcholinesterase inhibitors of potential interest for the treatment of
Alzheimer’s disease, Bioorg. Med. Chem. 6 (1998) 427e440.
[26] S. Hamulakova, L. Janovec, M. Hrabinova, P. Kristian, K. Kuca, M. Banasova,
J. Imrich, Synthesis, design and biological evaluation of novel highly potent
tacrine congeners for the treatment of Alzheimer’s disease, Eur. J. Med. Chem.
55 (2012) 23e31.
[27] A. Samadi, M. Estrada, C. Pérez, M.I. Rodríguez-Franco, I. Iriepa, I. Moraleda,
M. Chioua, J. Marco-Contelles, Pyridonepezils, new dual AChE inhibitors as
potential drugs for the treatment of Alzheimer’s disease: synthesis, bio-
logical assessment, and molecular modeling, Eur. J. Med. Chem. 57 (2012)
296e301.
[7] L. Piazzi, A. Cavalli, F. Colizzi, F. Belluti, M. Bartolini, F. Mancini, M. Recanatini,
V. Andrisano, A. Rampa, Multi-target-directed coumarin derivatives: hAChE
and BACE1 inhibitors as potential anti-Alzheimer compounds, Bioorg. Med.
Chem. Lett. 18 (2008) 423e426.
[8] X. Zhou, X.B. Wang, T. Wang, L.Y. Kong, Design, synthesis, and acetylcholi-
nesterase inhibitory activity of novel coumarin analogues, Bioorg. Med. Chem.
16 (2008) 8011e8021.
[9] J. Liu, V. Dumontet, A.L. Simonin, B.I. Iorga, V. Guerineau, M. Litaudon,
V.H. Nguyen, F. Gueritte, Benzofurans from styrax agrestis as acetylcholines-
terase inhibitors: structureeactivity relationships and molecular modeling
studies, J. Nat. Prod. 74 (2011) 2081e2088.
[10] Y. Rook, K.U. Schmidtke, F. Gaube, D. Schepmann, B. Wuensch, J. Heilmann,
J. Lehmann, T. Winckler, Bivalent b-carbolines as potential multitarget anti-
Alzheimer agents, J. Med. Chem. 53 (2010) 3611e3617.
[28] H. Tang, L.Z. Zhao, H.T. Zhao, S.L. Huang, S.M. Zhong, J.K. Qin, Z.F. Chen,
Z.S. Huang, H. Liang, Hybrids of oxoisoaporphine-tacrine congeners: novel
[11] H. Zheng, M.B.H. Youdim, M. Fridkin, Selective acetylcholinesterase inhibitor
activated by acetylcholinesterase releases an active chelator with neuro-
rescuing and anti-amyloid activities, ACS Chem. Neurosci. 1 (2010) 737e746.
[12] H. Zheng, M.B.H. Youdim, M. Fridkin, Site-activated multifunctional chelator
with acetylcholinesterase and neuroprotectiveeneurorestorative moieties for
Alzheimer’s therapy, J. Med. Chem. 52 (2009) 4095e4098.
[13] C. Martins, M.C. Carreiras, R. León, C. de los Ríos, M. Bartolini, V. Andrisano,
I. Iriepa, I. Moraleda, E. Gálvez, M. García, J. Egea, A. Samadi, M. Chioua, J. Marco-
Contelles, Synthesis and biological assessment of diversely substituted furo
[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as
novel tacrine analogues, Eur. J. Med. Chem. 46 (2011) 6119e6130.
[14] F. Belluti, L. Piazzi, A. Bisi, S. Gobbi, M. Bartolini, A. Cavalli, P. Valenti, A. Rampa,
Design, synthesis, and evaluation of benzophenone derivatives as novel ace-
tylcholinesterase inhibitors, Eur. J. Med. Chem. 44 (2009) 1341e1348.
[15] F. Belluti, M. Bartolini, G. Bottegoni, A. Bisi, A. Cavalli, V. Andrisano, A. Rampa,
Benzophenone-based derivatives: a novel series of potent and selective dual
inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-
amyloid aggregation, Eur. J. Med. Chem. 46 (2011) 1682e1693.
[16] M. Catto, A.A. Berezin, D. Lo Re, G. Loizou, M. Demetriades, A. De Stradis,
F. Campagna, P.A. Koutentis, A. Carotti, Design, synthesis and biological
evaluation of benzo[e][1,2,4]triazin-7(1H)-one and [1,2,4]-triazino[5,6,1-jk]
carbazol-6-one derivatives as dual inhibitors of beta-amyloid aggregation and
acetyl/butyryl cholinesterase, Eur. J. Med. Chem. 58 (2012) 84e97.
acetylcholinesterase and acetylcholinesterase-induced b-amyloid aggregation
inhibitors, Eur. J. Med. Chem. 46 (2011) 4970e4979.
[29] J.M. Contreras, I. Parrot, W. Sippl, Y.M. Rival, C.G. Wermuth, Design, synthesis,
and structureeactivity relationships of a series of 3-[2-(1-benzylpiperidin-4-
yl)ethylamino] pyridazine derivatives as acetylcholinesterase inhibitors,
J. Med. Chem. 44 (2001) 2707e2718.
[30] J.M. Contreras, Y.M. Rival, S. Chayer, J.J. Bourguignon, C.G. Wermuth, Ami-
nopyridazines as acetylcholinesterase inhibitors, J. Med. Chem. 42 (1999)
730e741.
[31] S. Utku, M. Gokce, I. Orhan, M.F. Sahin, Synthesis of novel 6-substituted-
3(2H)-pyridazinone-2-acetyl-2-(substituted/-nonsubstituted benzal)hydra-
zone derivatives and acetylcholinesrase and butyrylcholinesterase inhibitory
activities in vitro, Arzneimittelforschung 61 (2011) 1e7.
[32] K. Abouzid, M. Abdel Hakeem, O. Khalil, Y. Maklad, Pyridazinone derivatives:
design, synthesis, and in vitro vasorelaxant activity, Bioorg. Med. Chem. 16
(2008) 382e389.
[33] W.J. Coates, A. McKillop, One-pot preparation of 6-substituted 3(2H)-pyr-
idazinones from ketones, Synthesis (1993) 334e342.
[34] S. Lin, Z. Liu, Y. Hu, Microwave-enhanced efficient synthesis of diversified 3,6-
disubstituted pyridazines, J. Comb. Chem. 9 (2007) 742e744.
[35] C.S. Leung, S.S.F. Leung, J. Tirado-Rives, W.L. Jorgensen, Methyl effects on
protein-ligand binding, J. Med. Chem. 55 (2012) 4489e4500.
[36] G.L. Ellman, K.D. Courtney, V. Andres Jr., R.M. Featherstone, A new and rapid
colorimetric determination of acetylcholinesterase activity, Biochem. Phar-
macol. 7 (1961) 88e95.
[17] Y. Chen, J. Su, L. Fang, M. Liu, S. Peng, H. Liao, J. Lehmann, Y. Zhang, Tacrine-
ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl-
and butyrylcholinesterase inhibitors, J. Med. Chem. 55 (2012) 4309e4321.